ALK and cancer: Data for CT of other anti-cancer TT studied in elderly have been reviewed (anti-angiogenic treatment, anti EGFR, M-TOR inhibitors, BRAF and MEK inhibitors, C-KIT inhibitors, HER2 targeted therapies, tyrosine kinase inhibitors, or ALK inhibitors) and showed similar results that for younger patients [15].